Wells Fargo’s AbbVie ABBV Stock Holding History

Wells Fargo’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.44M	Hold	20,400	–	–	﹤0.01%	2691
2025 Q4	$4.66M	Sell	20,400 -600	-3%	-$137K	﹤0.01%	2747
2025 Q3	$4.86M	Sell	21,000 -2,900	-12%	-$591K	﹤0.01%	2606
2025 Q2	$4.44M	Sell	23,900 -127,000	-84%	-$23.6M	﹤0.01%	2573
2025 Q1	$31.6M	Buy	150,900 +145,100	+2,502%	+$28.2M	0.01%	1040
2024 Q4	$1.03M	Buy	5,800 +3,700	+176%	+$680K	﹤0.01%	3691
2024 Q3	$415K	Sell	2,100 -17,900	-90%	-$3.34M	﹤0.01%	4119
2024 Q2	$3.43M	Buy	20,000 +3,400	+20%	+$563K	﹤0.01%	2555
2024 Q1	$3.02M	Sell	16,600 -76,500	-82%	-$13.2M	﹤0.01%	2645
2023 Q4	$14.4M	Hold	93,100	–	–	﹤0.01%	1407
2023 Q3	$13.9M	Buy	93,100 +2,100	+2%	+$308K	﹤0.01%	1330
2023 Q2	$12.3M	Sell	91,000 -39,300	-30%	-$5.76M	﹤0.01%	1454
2023 Q1	$20.8M	Buy	130,300 +27,400	+27%	+$4.19M	0.01%	1114
2022 Q4	$16.6M	Buy	102,900 +102,500	+25,625%	+$15.7M	0.01%	1218
2022 Q3	$54K	Hold	400	–	–	﹤0.01%	4916
2022 Q2	$61K	Hold	400	–	–	﹤0.01%	4925
2022 Q1	$65K	Buy	+400	New	+$58.1K	﹤0.01%	5530
2021 Q3	–	Sell	-188,000	Closed	-$21.2M	–	6908
2021 Q2	$21.2M	Buy	+188,000	New	+$21.2M	﹤0.01%	1637
2021 Q1	–	Sell	-150,000	Closed	-$53K	–	6842
2020 Q4	$53K	Buy	+150,000	New	+$14.4M	﹤0.01%	5566
2020 Q3	–	Sell	-3,100	Closed	-$15K	–	6278
2020 Q2	$15K	Sell	3,100 -1,300	-30%	-$114K	﹤0.01%	5760
2020 Q1	$12K	Sell	4,400 -19,800	-82%	-$1.69M	﹤0.01%	5711
2019 Q4	$1K	Buy	24,200 +800	+3%	+$66.4K	﹤0.01%	6223
2019 Q3	$2K	Sell	23,400 -400	-2%	-$27.4K	﹤0.01%	6170
2019 Q2	$11K	Buy	23,800 +23,400	+5,850%	+$1.84M	﹤0.01%	5893
2019 Q1	$1K	Buy	+400	New	+$32.7K	﹤0.01%	5907
2017 Q4	–	Sell	-110,300	Closed	-$8K	–	6312
2017 Q3	$8K	Sell	110,300 -16,700	-13%	-$1.27M	﹤0.01%	5917
2017 Q2	$83K	Buy	127,000 +27,000	+27%	+$1.82M	﹤0.01%	5246
2017 Q1	$102K	Buy	100,000 +19,100	+24%	+$1.2M	﹤0.01%	5191
2016 Q4	$6K	Sell	80,900 -49,600	-38%	-$3.03M	﹤0.01%	5907
2016 Q3	$172K	Sell	130,500 -100	-0.1%	-$6.47K	﹤0.01%	4563
2016 Q2	$376K	Buy	130,600 +5,600	+4%	+$341K	﹤0.01%	4070
2016 Q1	$668K	Hold	125,000	–	–	﹤0.01%	3682
2015 Q4	$616K	Buy	125,000 +12,200	+11%	+$703K	﹤0.01%	3792
2015 Q3	$1.08M	Sell	112,800 -49,300	-30%	-$3.21M	﹤0.01%	3442
2015 Q2	$160K	Buy	+162,100	New	+$10.6M	﹤0.01%	4736
2014 Q4	–	Sell	-10,000	Closed	-$5K	–	6177
2014 Q3	$5K	Sell	10,000 -40,500	-80%	-$2.25M	﹤0.01%	5806
2014 Q2	$3K	Buy	50,500 +500	+1%	+$26.2K	﹤0.01%	5876
2014 Q1	$18K	Sell	50,000 -1,700	-3%	-$85.9K	﹤0.01%	5248
2013 Q4	$3K	Hold	51,700	–	–	﹤0.01%	5461
2013 Q3	$11K	Hold	51,700	–	–	﹤0.01%	5098
2013 Q2	$58K	Buy	+51,700	New	+$2.26M	﹤0.01%	4568

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wells Fargo's ABBV Position: Q1 2026 in Review

Wells Fargo reduced its AbbVie (ABBV) stake by 2.6% in Q1 2026, selling an estimated $52.8M and leaving 8,909,597 shares worth $1.94B. The position accounts for 0.37% of the portfolio, ranked #51.

Wells Fargo first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.11B in Q3 2025. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Wells Fargo held 8,909,597 shares of AbbVie worth $1.94B as of Q1 2026.
Wells Fargo sold 238,169 AbbVie shares in Q1 2026, an estimated $52.8M.
AbbVie made up 0.37% of Wells Fargo's portfolio in Q1 2026, its #51 holding.
Wells Fargo first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
Wells Fargo's AbbVie position peaked at $2.11B in Q3 2025.
4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.